Purpose-To report the ocular phenotype in patients with autosomal recessive bestrophinopathy and carriers, and to describe novel BEST1 mutations.
in all patients. A cystoid maculopathy was seen in all but one patient. In 1 patient, the location of the vitelliform material was seen to change over a follow-up period of 3 years despite relatively stable vision. Visual acuity and fundus changes were unresponsive to topical and systemic carbonic anhydrase inhibitors and systemic steroids. Carriers had normal ocular examinations including normal fundus autofluorescence. Three novel mutations were detected.
Conclusion-Three novel BEST1 mutations are described, suggesting that many deleterious variants in BEST1 resulting in haploinsufficiency are still unknown. Mutations causing autosomal recessive bestrophinopathy are mostly located outside of the exons that usually harbor vitelliform macular dystrophy-associated dominant mutations.
Keywords
autosomal recessive bestrophinopathy; BEST1 gene; deleterious mutations; vitelliform BEST1 (VMD2) is a gene located on the long arm of chromosome 11 (11q12.3) that encodes for the 585 amino acid transmembrane protein bestrophin 1, located on the basolateral aspect of retinal pigment epithelial (RPE) cells. 1 The exact function of bestrophin 1 is still not unequivocally characterized, but it is linked to transepithelial chloride flow possibly by controlling Ca 2+ channels in the RPE. [1] [2] [3] Mutations in BEST1 therefore affect RPE metabolism, and by consequence outer retinal function with which the RPE is intimately associated. Over 200 mutations in BEST1 have been identified and published. 1, 3, 4 Mutations are associated with Best vitelliform macular dystrophy (VMD, MIM 153700), adult-onset vitelliform macular dystrophy (MIM 608161), retinitis pigmentosa 50 (RP50, MIM 613194), and autosomal dominant vitreoretinochoroidopathy (MIM 193220) . These diseases are all caused by autosomal dominant mutations. Recently, a phenotype caused by autosomal recessive mutations in BEST1 was described: autosomal recessive bestrophinopathy (ARB, OMIM 611809).
Autosomal recessive bestrophinopathy is a rare ocular disease. It was defined by Burgess et al 1 in 2008, although the same condition with compound heterozygous mutations in VMD2 had been described 2 years earlier. 5 It results from biallelic mutations in BEST1 and is characterized by a multifocal vitelliform dystrophy with subretinal fluid. An association with hypermetropia and angle closure has been described. 1 Herein, we review the clinical features and mutation analysis of four families with ARB.
Materials and Methods

Patients and Clinical Analyses
All patients underwent a complete ophthalmic examination by a retinal physician. This included best-corrected visual acuity, cycloplegic refraction, slit-lamp biomicroscopy, and dilated funduscopy. All patients underwent color fundus photography, fundus autofluorescence imaging, and spectral domain optical coherence tomography. In addition, Patient 4 underwent fluorescein and indocyanine green angiography. When possible, patients had electroretinography and electrooculography performed under the International Society for Clinical Electrophysiology of Vision standards. 6, 7 Peripheral blood was drawn for genetic testing. Patients provided written informed consent for all procedures, which were approved by the Ethics Committees of the sites involved and adhered to the Declaration of Helskinki (Institutional Review Board protocol #AAAB6560 Columbia University).
Genetic Analyses
All 11 exons of BEST1 gene were sequenced by Sanger direct sequencing method to obtain sequences for all coding sequences, the noncoding Exon 1, and 50bp of adjacent intronic sequences of each exon. Primer sequences are available on request. Messenger RNA was isolated from venous blood using QIAamp RNA Blood Mini Kit (QIAGEN Cat. No. 75142) with a fast spin-column procedure. Genomic DNA is eliminated by pre-treating the RNA sample with DNase I, Amplification Grade (Invitrogen Cat. No. 18068-015 DNase I Amplification Grade; Invitrogen, Carlsbad, CA). The primer pair was designed to encompass BEST1 Exons 1 and 2. Forward primer was in the Exon 1 of BEST1, 5′ACCAGCCTAGTCGCCAGA3′ (1) and the reverse primer in the Exon 2 of BEST1, 5′GCGGATGATGTAGTAGCAGAG3′ (2). The final concentration for each primer was 0.2 μmol. The thermal cycling conditions were established using a ABI 9700 thermocycler (Applied Biosystems, Foster City, CA). Efficient complementary DNA synthesis was achieved in a 30-minute incubation at 55° C. Polymerase chain reaction (PCR) amplification consisted of 40 cycles of 94°C for 15 seconds, 65° C for 30 seconds, and 68°C for 1 minute. We used 1 cycle 68°C for 5 minutes for final extension.
Results
Five patients from four families with genetically confirmed ARB were identified. Mean age was 16 years (range, 6-42 years). Two patients (Patients 3 and 5) were the product of a consanguineous marriage. All patients presented with reduced visual acuity and bilateral, subretinal yellowish deposits within the posterior pole that showed increased autofluorescence on fundus autofluorescence imaging. On spectral domain optical coherence tomography, submacular fluid and subretinal changes suggestive of vitelliform material were present in all patients. In 1 patient (Patient 4), the location of the vitelliform material was seen to change over a follow-up period of 3 years with relatively stable vision. A cystoid maculopathy was seen in all but one patient (Patient 5). Visual acuity and fundus changes were unresponsive to topical and systemic carbonic anhydrase inhibitors and systemic steroids. Both parents of Patient 3 had normal ocular examinations including normal 20/20 vision, normal fundus autofluorescence, and a completely normal spectral domain optical coherence tomography. Clinical features and investigations are described below and summarized in Figures 1-4 and Tables 1-3.
Family 1, Patients 1 and 2
A 11-year-old otherwise healthy white boy presented with a 6-month history of reduced vision and central scotoma (Figure 1 ). His vision was 20/25 in both eyes, and there was no evidence of angle closure. Bilateral, multifocal subretinal hyperautofluorescent yellowish deposits extended from the posterior poles up to the equator. Cystoid macular edema and shallow serous macular detachments were present in both eyes. Treatment with topical nepafenac 0.1% (1 month) and prednisone 10 mg PO (3 weeks) failed to improve vision or the fundus appearance. His 7-year-old brother was subsequently found to have almost identical clinical findings, whereas his 9-year-old sister and parents were unaffected.
Compound heterozygous BEST1 variants were identified in the affected patients. The first was a novel c.728C>A; p.Ala243Glu missense mutation in Exon 7. In the same codon, previously reported BEST1 variants include p.Ala243Val 8 and p.Ala243Thr. 9 Both the nucleotide and the amino acid are highly conserved in this position of BEST1. All predictive programs suggest that the variant is disease-causing or disease-damaging. Therefore, it is highly likely that this variant is deleterious as are (almost) all BEST1 variants implicated in ARB. The second mutation, the previously described c.598C>T; p.Arg200* mutation, 1 generates a stop codon and results in a truncated protein at position 200.
Family 2, Patient 3
A 6-year-old asymptomatic, U.S.-born African boy was noted to have poor vision by his schoolteacher (Figure 2 ). A history of consanguinity was present in the family, with his parents being first cousins. Bilateral, multifocal curvilinear subretinal hyperautofluorescent yellowish deposits were present in both eyes with cystic edema and subretinal fluid at the maculae. Subfoveal choroidal thicknesses were 586 μm in the right eye and 482 mm in the left eye. Trials of topical dorzolamide 2% 3 times a day in both eyes (6 weeks), acetazolamide 500 mg nocte (2 months), and prednisone failed to improve vision or the clinical appearance. Three years after first presentation, the vision remained stable at 20/80 in both eyes. All other family members were clinically unaffected.
A novel, homozygous deleterious mutation was identified in the proband in the in-frame deletion of 3 nucleotides, c.847_849delTTC, which results in a homozygous deletion of phenylalanine at position 283, p.Phe283del.
Family 3, Patient 4
A 12-year-old otherwise healthy, emmetropic Puerto Rico-born U.S. boy was noted to have reduced vision on routine eye examination. Bilateral, confluent curvilinear subretinal hyperautofluorescent yellowish vitelliform deposits became more multifocal and dispersed over 3 years of follow-up ( Figure 3 ). Bilateral multifocal serous retinal detachments and cystic edema involved both maculae. Subfoveal choroidal thickness was 537 μm in the right eye and 527 μm in the left eye. Oral prednisone 60 mg daily (3 months), topical dorzolamide 2% 3 times a day in both eyes (6 weeks), and oral acetazolamide (6 weeks) were trialed to reduce the cystoid maculopathy with no clinical response.
A previously described 10 homozygous c.821C>G; p.Pro274Arg variant was detected. This variant of a highly conserved nucleotide and an amino acid is predicted to be deleterious by all predictive programs.
Family 4, Patient 5
A 42-year-old woman whose vision problems started at 5 years of age was recently noticing deteriorating central vision (Figure 4) . She was the product of a first-cousin marriage. A white-yellow vitelliform lesion was present at the left fovea, and RPE and retinal atrophy within the posterior poles. Shallow subretinal but not intraretinal fluid was present at both maculae. Subfoveal choroidal thickness was 370 μm in both eyes. A trial of oral acetazolamide 500 mg failed to improve the vision.
A splice site variant, c.-29+5G>A (IVS1+5G>A), was identified in Intron 1 of BEST1 in the donor site of the first untranslated exon. This exon is usually not screened for variants in patients with BEST1-associated diseases. As shown in Table 3 , the variant practically abolishes the splice donor site as predicted by all programs. To confirm the functional consequences of this variant, we performed the splicing studies through an "illegitimate transcript" strategy. Although the BEST1 gene is expressed only in the retinal pigment epithelium, it can also be detected by PCR at very low levels from other cells, such as the leucocytes in peripheral blood. We isolated messenger RNA from a blood sample of Patient 5 and performed PCR encompassing two exons. As seen in Figure 5 , the messenger RNA of a normal control produced the expected PCR fragment in the situation where the splicing had been performed correctly. In this patient, homozygous for the IVS1+5G>A variant, the expected PCR product of 234bp was not detected and it was clear that the splicing of BEST1 gene was incorrect, very likely resulting in no functional messenger RNA and, consequently, no BEST1 protein.
Discussion
Autosomal recessive bestrophinopathy is a rare disease, with only a few case series described. 1, 5, 10, [12] [13] [14] [15] [16] [17] The timing of presentation is variable, with patients as young as 3 years 10 and as old as 45 years 13 being reported. Patients are typically hyperopic and present with moderately reduced vision, bilateral multifocal hyperautofluorescent vitelliform lesions with foveal involvement, and shallow retinal detachment. Scotopic and photopic full-field electroretinographies usually diminish with age, and the electrooculography shows a reduced or absent light rise (Arden ratio 1.0).
Our patients' phenotypes are all very consistent with these previous reports of ARB, although some interesting observations can be made. In one case (Patient 1), the vitelliform material appeared to emanate from the RPE on spectral domain optical coherence tomography. In 3 patients (Patients 1, 3, and 4), the retinal architecture was abnormal with thickening of Band 2 (traditionally described as the inner segment/outer segment junction), even in extramacular attached retina. Although it would be easy to ascribe this to vitelliform material, this area of "Band 2" thickening did not uniformly hyperautofluoresce and may instead represent elongation of degenerate photoreceptors. In four patients (Patients 1-4) , the presence of a cystoid maculopathy was striking. This had been reported previously 10, 12, 13, 16, 17 and may represent perturbation of the blood-retinal barrier. Inflammation is less likely given the lack of anterior chamber or vitreous cells, optic neuritis, or vasculitis in all these patients. This cystic edema was absent in the eldest patient (Patient 5, 42 -years old). It is possible that with time, the multifocal vitelliform material in pediatric cases of ARB resolves. Subfoveal choroidal thickness was measured by enhanced depth imaging optical coherence tomography in three patients (Patients 3-5), with thickening in Patient 5. Unfortunately, not only has choroidal thickness not been described in ARB before, but normative data only apply to adults 19 
Patient 4 had a 3-year follow-up and demonstrated dispersion and a change in location of the vitelliform material from superior to nasal to the optic disks. This is one of the longest follow-ups of a patient with ARB that we are aware of, and the first to describe fluctuation and dispersion in appearance. This patient also had indocyanine green angiography, which has only been described once before in ARB. 15 There was bilateral midphase hyperfluorescence at both maculae, which colocalized with the area of fluorescein leakage. This may represent leakage of indocyanine green dye into the shallow neurosensory detachments or choroidal hyperpermeability. Lipofuscin-rich vitelliform material does not normally stain with indocyanine green dye. 20 In VMD, which has similarities to ARB, small, peripheral hyperfluorescent spots on indocyanine green angiography have been described, 20 and histopathology has shown involvement not only of the retina and RPE but also of fibrillar material and electron-dense particles on electron microscopy within the choroid. 21, 22 Attempts at managing the cystic macular changes with topical and systemic carbonic anhydrase inhibitors and systemic steroids proved unsuccessful. However, it must be emphasized that the medications, dosages, and durations were not standardized, and Patient 2 was not prescribed any treatment. , suggesting that many deleterious variants in BEST1 resulting in loss of function are still unknown. It has been hypothesized that the ARB phenotype is caused by mutations that occur in the intracellular loop of the protein 10 or that the presence of two null alleles lead to disease. We agree that autosomal recessive mutations in BEST1 that lead to ARB are most likely deleterious while autosomal dominant mutations in BEST1 lead to VMD because of a dominant negative effect. Based on our results and reviewing those previously described, we also suggest that the dominant and recessive mutations mostly do not overlap and that the recessive mutations are located throughout the gene.
Other conditions can mimic the phenotypic appearance of ARB. These include multifocal Best disease, adult-onset VMD, multifocal pattern dystrophy associated with peripherin/RDS mutations, acute, exudative polymorphous vitelliform maculopathy, and paraneoplastic syndromes or metastases. [23] [24] [25] [26] In addition, chronic, central serous choroidopathy can present with serous retinal detachments, cystoid maculopathy, and subretinal fibrin, although fibrin does not hyperautofluoresce. Boon et al 23 studied clinical and genetic heterogeneity in 15 patients with a multifocal vitelliform phenotype. Nine of these patients carried a BEST1 mutation and one a peripherin/RDS mutation. Not only were the phenotypic appearance of patients with BEST1 mutations diverse, but some of the patients without mutations in BEST1 presented with a fundus appearance identical to the patients we describe in this study. Incorrect initial diagnoses in our patients included acute exudative polymorphous vitelliform maculopathy, Vogt-Koyanagi-Harada disease, and fundus flavimaculatus. Comprehensive screening by sequencing of the entire BEST1 gene is therefore essential for the correct classification of these patients.
In summary, we report five patients from four families where affected individuals presented with ARB. Genetic analyses confirmed the disease in all families and showed segregation of likely deleterious, homozygous, or compound heterozygous mutations in BEST1 with the disease phenotype. This study highlights several important points for the management of ARB: horizontal scans through the maculae reveal cystoid macular changes and shallow serous macular detachments in both eyes. There is thickening and hyperreflectivity at the inner segment/outer segment photoreceptor junction ("Band 2," arrows). D. Spectral domain optical coherence tomography horizontal scan through the superior vascular aracade, 3 months after presentation colocalizes the vitelliform material to the subretinal space. The material appears to be emanating from the RPE (stars). E. Genetic screening of the family members confirmed the segregation of the two BEST1 mutations with the disease. there are bilateral, multifocal serous retinal detachments involving the maculae and cystoid changes in the macula. There is thickening and hyperreflectivity at the inner segment/outer segment photoreceptor junction ("Band 2", arrows). Subfoveal choroidal thickness measured 537 μm in the right eye and 527 μm in the left eye with enhanced depth imaging. shallow subretinal fluid is seen at both maculae but not cystoid maculopathy. The subretinal vitelliform deposit is seen in the left eye. Subfoveal choroidal thickness measured 370 μm in both eyes with enhanced depth imaging. 
